Quick Takeaways
- JANUS HENDERSON GROUP PLC filed SCHEDULE 13G/A for LIGAND PHARMACEUTICALS INCORPORATED Common Stock (LGND).
- Disclosed ownership: 5.5%.
- Date of event: 30 Jun 2025.
JANUS HENDERSON GROUP PLC - 30 Jun 2025 SCHEDULE 13G/A Report for LIGAND PHARMACEUTICALS INCORPORATED Common Stock (LGND)
- Filing Manager
- JANUS HENDERSON GROUP PLC
- Reporting Manager
- JANUS HENDERSON GROUP PLC
- Symbol
- LGND
- Shares outstanding
- 19,286,073 shares
- Disclosed Ownership
- 1,060,734 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 11:43:32 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 14 May 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JANUS HENDERSON GROUP PLC disclosed 5.5% ownership in LIGAND PHARMACEUTICALS INCORPORATED Common Stock (LGND) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 14 May 2025.
- Current filing was accepted on 14 Aug 2025, 11:43.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 5.5% | 1,060,734 | 0 | 1,060,734 | Kristin Mariani | Head of North America Compliance, CCO |